Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pancreas Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia, thrombocyto...
Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia, thrombocytopenia, diarrhea, nausea-vomiting, anorexia, asthenia, weight loss and peripheral sensory neuropathy. Therefore, its indication is limited to patients in good general condition with a Performance Status of 0 or 1 (WHO classification). In practice, it is interrupted upon the occurrence of grade 3-4 toxicities, hematological and / or clinical, which very often causes deterioration in the performance status and quality of life of patients. To date, there is no prospective study assessing the qualitative and quantitative impact of FOLFIRINOX in real time on the daily life of patients with pancreatic cancer. Such monitoring would allow early identification of the deterioration or improvement in the health of these fragile patients while they are not hospitalized, and trigger proactive interventions when necessary, in order to avoid rapid deterioration of the patient leading to hospitalization and often to the interruption of a generally effective treatment. It is in this context that the study presented here proposes to monitor the rhythms, symptoms and body weight of patients with advanced pancreatic cancer during the month following the 1st cycle of FOLFIRINOX in conventional administration using the platform. PiCADo mobile.
Tracking Information
- NCT #
- NCT04263948
- Collaborators
- Not Provided
- Investigators
- Not Provided